Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens

Journal of Human Virology

Volumn 4, Issue 4, 2001, Pages 217-222

  Ross, L ^a   Henry, K ^a   Paar, D ^a   Salvato, P ^a   Shaefer, M ^a   Fisher, R ^a   Liao, Q ^a   St Clair, M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

D4T; Mutations; Stavudine; ZDV; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS RESISTANCE;

ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THYMIDINE; VIREMIA; ZIDOVUDINE;

EID: 0035159223     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
2. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy
3. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
4. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
5. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy
6. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
7. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy
8. Mutations conferring resistance to zidovlidine diminish the antiviral effect of stavudine plus didanosine
9. Emergence of zidovudine and multi-nucleoside resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
10. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
11. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine
12. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction
13. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
14. Significance of amino acid variation at human immunodeficiency virus type I reverse transcriptase residue 210 for zidovudine susceptibility
15. Twice-daily triple nucleoside intensification treatment with a lamivudine/zidovudine combination tablet, plus abacavir, sustains HIV-1 suppression over 48 weeks: Results of the TARGET study
16. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
17. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
18. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
19. Identification of insertion mutations in H1V-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors
20. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
21. I178M in HIV-1 RT is associated with in vitro d4T resistance and d4T failure in some therapy-naive pediatric subjects
22. Stavudine resistance: An update on susceptibility following prolonged therapy
23. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
24. Occurrence of thymidine-associated mutations in naive patients treated more than 6 months by stavudine/lamivudine bi-therapy combination and tri-therapies including stavudine/didanosinie or stavudine/lamivudine
25. Selection of zidovudine resistance mutations by zidovudine or stavudinebased regimens and relationship to subsequent virologic response in ACTG 370
26. Zidovudine genotypic and phenotypic resistance arising in patients never exposed to zidovudine
27. Prevalence of zidovudine and lamivudine-resistance-related mutation in the absence of active zidovudine or lamivudine use in a large, multi-centered, comparative trial of genotyping and standard of care: The Havanna trial
28. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
29. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
30. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors
31. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
32. Differential removal of thymidine analog nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates